ClinicalTrials.Veeva

Menu

The Study of LTBP1 of Postmenopausal Women Osteoporosis Molecular Mechanism of Kidney Yang Deficiency Syndrome

F

Fujian Academy of Traditional Chinese Medicine

Status

Completed

Conditions

Kidney Yang Deficiency Syndrome

Study type

Observational

Funder types

Other

Identifiers

NCT01940380
20130305

Details and patient eligibility

About

Postmenopausal Osteoporosis is characterized by a decrease in bone mass as well as a deterioration of the bone architecture resulting in an increased risk of fracture,which is directly related to the lack of estrogen and also associated with a variety of genetic and acquired factors. Previous studies have found that POP molecular regulation mechanism of kidney Yang deficiency syndrome may be associated with LTBP1 gene expression.

This topic using RT-PCR and Western Blot detection POP of kidney Yang deficiency group and healthy group LTBP1 mRNA and proteion's expression level,validate LTBP1 relevance to POP the kidney Yang deficiency syndrome.To provide a scientific basis for clinical treatment.

Enrollment

25 estimated patients

Sex

Female

Ages

45 to 75 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • • The Participants who volunteer to be test subjects, and can accept experimental drugs, and promise to finish the course should sign the informed consent.

    • Female ages 45 to 75 had gone through natural menopause before two years
    • In accordance with the western medicine diagnostic criteria of osteoporosis and belong to kidney Yin deficiency syndrome differentiation of traditional Chinese medicine certificate;
    • In accordance with the western medicine diagnostic criteria;
    • In accordance with TCM diagnostic methods; .If any of the above answers are no, The subjects couldn't in the study

Exclusion criteria

  • Do not accord with standard of the western medicine diagnosis and TCM diagnostic methods

    • Age: <44 and > 76 years old;
    • With hyperparathyroidism, osteomalacia, rheumatoid arthritis, multiple myeloma and other serious complications such as secondary osteoporosis; Late or deformity, disability, loss of labor;
    • With cardiovascular, cerebrovascular, liver, kidney and hematopoietic system and other serious primary diseases;
    • Psychosis or alzheimer's patients;
    • Nearly three months, the use of hormone replacement therapy (HRT) and taking calcitonin, nearly six months has used double phosphonic acid salt for 15 days, etc.;
    • This medicine allergic constitution or composition of known to have allergies;
    • In a critical condition, It's difficult to make exact evaluators to efficacy and safety of the new drugs;

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems